Quantcast

Latest Azacitidine Stories

2008-10-27 12:00:10

Celgene International has announced that its cancer drug, Vidaza, has received a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use for the treatment of adult patients with myelodysplastic syndromes, acute myeloid leukemia and chronic myelomonocytic leukemia. The positive opinion includes important survival data from the AZA-001 trial in higher-risk myelodysplastic syndromes (MDS) patients. The Committee for Medicinal Products for Human Use...

2008-09-12 09:00:09

Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) (NASDAQ:CYCCP) announced that it has advanced sapacitabine into Phase 2 development as a second-line treatment for myelodysplastic syndromes (MDS). The MDS study is designed as a protocol amendment expanding the ongoing Phase 2 trial of sapacitabine in elderly patients with acute myeloid leukemia (AML) to include a cohort of patients with MDS. MDS are a group of hematologic cancers in which the bone marrow becomes unable to produce a sufficient...

2008-08-25 12:01:19

The Moffitt Cancer Center announced today that Dr. Alan List, Physician-in-Chief, was one of the key investigators in a VIDAZA (azacitidine) clinical trial (AZA-001) whose results the U.S. Food & Drug Administration (FDA) has approved to add to the drug's label. In May 2004, VIDAZA was the first drug approved by the FDA for the treatment of MDS. The AZA-001 study is the largest ever phase III; multi-center randomized trial involving higher-risk MDS patients. This study found that...

2008-08-22 12:00:16

The Myelodysplastic Syndromes (MDS) Foundation supports the decision by the U.S. Food & Drug Administration (FDA) to extend the label for VIDAZA (azacitidine) to include data from the AZA-001 clinical trial. Results from the trial found that azacitidine is the only agent which has been shown to extend survival in MDS patients. Data from the AZA-001 trial was recently presented at this year's American Society of Clinical Oncology (ASCO) Annual Meeting and found that azacitidine nearly...

2008-08-22 06:00:10

Celgene has announced that Vidaza has received expanded FDA approval to reflect new overall survival achieved in the AZA-001 survival study of patients with higher-risk myelodysplastic syndromes. This expanded indication supplements the 2004 FDA authorization of Vidaza as the first therapy approved in the US for the treatment of patients with all five French American British subtypes of myelodysplastic syndromes (MDS), the company said. Vidaza is also the first and only drug to show a...

2008-08-21 12:01:28

The Aplastic Anemia & MDS International Foundation (AA&MDSIF) is pleased to inform patients that the U.S. Food & Drug Administration (FDA) has expanded the label for VIDAZA (azacitidine) to include data from the AZA-001 trial, which found that Vidaza is the only agent that extends survival in MDS (myelodysplastic syndromes) patients. Vidaza was also shown to delay progression to acute myelogenous leukemia (AML) in patients with MDS. Roughly 30 percent of patients diagnosed with...

2008-08-21 09:00:22

Celgene Corporation (Nasdaq:CELG) today announced VIDAZA (azacitidine) received expanded U.S. Food and Drug Administration (FDA) approval to reflect new overall survival achieved in the AZA-001 survival study of patients with higher-risk myelodysplastic syndromes (MDS). This expanded indication supplements the 2004 FDA authorization of VIDAZA as the first therapy approved in the U.S. for the treatment of patients with all five French American British (FAB) subtypes of MDS. VIDAZA is also the...

2008-06-26 12:02:01

MethylGene has initiated a Phase II clinical trial evaluating MGCD0103, an isoform-selective histone deacetylase inhibitor product candidate, in combination with Vidaza, a DNA demethylating agent, in patients with high-risk myelodysplastic syndromes or acute myeloid leukemia. The study is a three-arm, randomized trial which will enroll up to 180 patients at cancer centers in North America and Europe. Charles Craddock, professor of haemato-oncology at University of Birmingham, UK, said:...

2008-06-25 09:01:48

MONTREAL, QUEBEC--(Marketwire - June 25, 2008) - MethylGene Inc. (TSX:MYG) announced today the initiation of a Phase II clinical trial (Trial 013) evaluating MGCD0103, an isoform-selective histone deacetylase (HDAC) inhibitor product candidate, in combination with Vidaza(R) (azacitidine for injection), a DNA demethylating agent, in patients with high-risk myelodysplastic syndromes (MDS) or acute myeloid leukemia (AML). The study is a three-arm, randomized trial which will enroll up to 180...

2008-06-18 00:00:05

Celgene Corporation David Gryska, 908-673-9059 Sr. Vice President and Chief Financial Officer or Brian P. Gill, 908-673-9530 Vice President, Corporate Communications Logo: http://www.celgene.com Celgene International Sarl (Nasdaq: CELG): -- Study of VIDAZA in Higher-Risk MDS Patients Reports Improved Overall Survival -- New Analysis of Phase III Studies Shows REVLIMID Plus Dexamethasone Yielded an Estimated Mean Survival of 5.6 Life Years for Patients with Multiple...


Word of the Day
snash
  • To talk saucily.
  • Insolent, opprobrious language; impertinent abuse.
This word is Scots in origin and probably imitative.